This case highlights the vulnerability of routine serologic testing to misclassification of rare weak ABO subgroups. Integration of molecular genotyping with serologic testing can provide resolution of ABO discrepancies and enhance transplant safety. This case demonstrates a policy-relevant gap in current ABO determination workflows for deceased donors. Lack of standardized inter-laboratory data sharing and limited access to rapid molecular testing may unnecessarily restrict organ utilization.
Dionne et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: